Spero Therapeutics (SPRO) Share-based Compensation (2016 - 2026)

Spero Therapeutics (SPRO) has reported Share-based Compensation for 11 consecutive years, with $21.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 726.08% year-over-year to $21.3 million; the trailing twelve-month figure through Jun 2026 stood at $21.3 million (up 726.08% YoY), and the FY2025 full-year result was $4.3 million, down 44.5% from the prior year.
• Share-based Compensation steadied at $21.3 million in Q2 2026 per SPRO's latest filing, from $21.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $21.3 million in Q1 2026 and bottomed at $1.0 million in Q4 2025.
• Historically, Share-based Compensation has averaged $7.2 million across 5 years, with a median of $2.9 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation tumbled 75.88% in 2024, then soared 726.08% in 2026.
• Over 5 years, Share-based Compensation stood at $2.5 million in 2022, then declined by 20.02% to $2.0 million in 2023, then fell by 24.74% to $1.5 million in 2024, then sank by 33.0% to $1.0 million in 2025, then jumped by 2019.67% to $21.3 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $21.3 million, $21.3 million, and $1.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.